Intra-Cellular gets another FDA Nod for Caplyta, this time for Bipolar Disorder
Synopsis: CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as…
Synopsis: CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as…
KEYPOINTS: Janssen has won approval from the European Commission for Byannli, a six-month formulation of Paliperidone Palmitate, two months after receiving a…